topiramate + phenytoin (Johnson & Johnson)

This entry refers to the comparative evaluation of topiramate and phenytoin as monotherapies in the treatment of new-onset epilepsy, specifically within the context of a Phase 3 clinical trial (NCT00210782) sponsored by Johnson & Johnson Pharmaceutical Research & Development. Topiramate is a broad-spectrum antiepileptic drug that modulates voltage-gated sodium channels, enhances GABAergic transmission through positive allosteric modulation of GABA-A receptors, and antagonizes AMPA/kainate glutamate receptors. Phenytoin is a classic antiepileptic that primarily acts by blocking voltage-gated sodium channels in their inactive state. The trial compared the efficacy and safety of these two agents in patients requiring rapid initiation of treatment, finding that while noninferiority for seizure control was not definitively established, topiramate demonstrated superior retention and a favorable tolerability profile without requiring dose titration.

Brand names

TopamaxDilantin

Other names

topiramate, phenytoin